Everything below concerns Peptide content. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
| Property | Value | Notes |
|---|---|---|
| Dosage form | Lyophilized powder in sealed vial | Reconstituted before analytical or laboratory use |
| Reconstitution solvent | Sterile or bacteriostatic water | Bacteriostatic water limits microbial growth in multi-use vials |
| Typical working pH | Near neutral, buffered | Strongly acidic or basic conditions promote degradation |
| Stability indicator | Loss of main HPLC peak over time | Aggregation and oxidation are common degradation routes |
| Documentation | Batch certificate of analysis | Covers identity, purity and sometimes sterility testing |
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Sitagliptin (Januvia) has a novel structure with β-amino amide derivatives (Figure 7). Since sitagliptin has shown excellent selectivity and in vivo efficacy it urged researchers to inspect the new structure of DPP-4 inhibitors with appended β-amino acid moiety. Further studies are being developed to optimize these compounds for the treatment of diabetes. In October 2006 sitagliptin became the first DPP-4 inhibitor that got FDA approval for the treatment of type 2 diabetes. Crystallographic structure of sitagliptin along with molecular modeling has been used to continue the search for structurally diverse inhibitors. A new potent, selective and orally bioavailable DPP-4 inhibitor was discovered by replacing the central cyclohexylamine in sitagliptin with 3-aminopiperidine. A 2-pyridyl substitution was the initial SAR breakthrough since that group plays a significant role in potency and selectivity for DPP-4. It has been shown with an X-ray crystallography how sitagliptin binds to the DPP-4 complex: 1. The trifluorophenyl group occupies the S1-pocket 2. The trifluoromethyl group interacts with the side chains of residues Arg358 and Ser209. 3. The amino group forms a salt bridge with Tyr662 and the carboxylated groups of the two glutamate residues, Glu205 and Glu206. 4. The triazolopiperazine group collides with the phenyl group of residue Phe357
Sect. Andinium W.Becker (113) S America Sect. Chamaemelanium Ging. s.lat. (61) N America, northeast Asia (includes Dischidium, Orbiculares) Subsect. Chamaemelanium Subsect. Nudicaules Subsect. Nuttalianae Sect. Chilenium W.Becker (8) southern S America Sect. Danxiaviola W. B. Liao et Q. Fan (1) China Sect. Delphiniopsis W.Becker (3) western Eurasia: southern Spain; Balkans Sect. Erpetion (Banks) W.Becker (11–18) eastern Australia; Tasmania Sect. Leptidium Ging. (19) S America Sect. Melanium Ging. (125) western Eurasia (pansies) Sect. Nosphinium W.Becker s.lat. (31–50) N, C and northern S America; Beringia; Hawaii Sect. nov. A (V. abyssinica group) (1–3) Africa: equatorial high mountains Sect. nov. B (V. spathulata group) (7–9) western and central Asia: northern Iraq to Mongolia Sect. Plagiostigma Godr. (120) northern hemisphere (includes Diffusae) Grex Primulifolia Sect. Rubellium W.Becker (3–6) S America: Chile Sect. Sclerosium W.Becker (1–4) northeastern Africa to southwestern Asia Sect. Tridens W.Becker (2) southern S America Sect. Viola s.str. (Rostellatae nom. illeg.) (75) northern hemisphere (violets) (includes Repentes) Subsect. Rostratae Kupffer (W.Becker) Subsect. Viola Sect. Xylinosium W.Becker (3–4) Mediterranean region
Kamiyah as well as all the patients found through the column became the breakthrough needed to begin proper human research towards a diagnosis and treatment of the gene mutation. While Kamiyah was not able to technically receive a diagnosis for her illness, she created the pathway for research into possible treatments for patients in the future.
=== Currency === The new state continued to use the Pound sterling from its inception; there is no reference in the Treaty or in either of the enabling Acts to currency. Nonetheless, and within a few years, the Dáil passed the Coinage Act, 1926 (which provided for a Saorstát [Free State] coinage) and the Currency Act, 1927 (which provided inter alia for banknotes of the Saorstát pound). The new Saorstát pound was defined by the 1927 Act to have exactly the same weight and fineness of gold as was the sovereign at the time, making the new currency pegged at 1:1 with sterling. The State circulated its new national coinage in December 1928, marked Saorstát Éireann and a national series of banknotes. British coinage remained acceptable in the Free State at an equal rate. In 1937, when the Free State was superseded by Ireland (Éire), the pound became known as the "Irish pound" and the coins were marked Éire as from 1939. No coins dated 1938 were struck for circulation in Ireland, but the 1938 1 Penny and Half Crown exists as pattern coins.
Sources: en.wikipedia.org
== Chemistry == MCD peptide is a cationic 22-amino acid residue peptide with two disulfide bridges. Although the MCD peptide sequence shows similarity with apamin, they have different toxic properties. MCD peptide belongs to a large family composed of numerous derivatives detecting specific targets and displaying different toxic effects.
Adult T-cell leukemia/lymphoma Angiocentric lymphoma (extranodal natural killer cell lymphoma, nasal-type NK lymphoma, NK/T-cell lymphoma, polymorphic/malignant midline reticulosis) Angioimmunoblastic T-cell lymphoma (angioimmunoblastic lymphadenopathy with dysproteinemia) Blastic NK-cell lymphoma CD30+ cutaneous T-cell lymphoma (primary cutaneous anaplastic large cell lymphoma) Cutaneous lymphoid hyperplasia (borrelial lymphocytoma, lymphadenosis benigna cutis, lymphocytoma cutis, pseudolymphoma, pseudolymphoma of Spiegler and Fendt, sarcoidosis of Spiegler and Fendt, Spiegler–Fendt lymphoid hyperplasia, Spiegler–Fendt sarcoid) Cutaneous lymphoid hyperplasia with bandlike and perivascular patterns Cutaneous lymphoid hyperplasia with nodular pattern (nodular pattern of cutaneous lymphoid hyperplasia) Diffuse large B-cell lymphoma (primary cutaneous large B-cell lymphoma) Granulocytic sarcoma (chloroma, myeloid sarcoma) Granulomatous slack skin Hairy-cell leukemia Hodgkin's disease Ichthyosis acquisita (acquired ichthyosis) IgG4-related skin disease Intravascular large B-cell lymphoma (angiotropic large cell lymphoma, intralymphatic lymphomatosis, intravascular lymphomatosis, malignant angioendotheliomatosis) Jessner lymphocytic infiltrate of the skin (benign lymphocytic infiltration of the skin, Jessner lymphocytic infiltration of the skin, Jessner–Kanof lymphocytic infiltration of the skin, lymphocytic infiltrate of Jessner) Kikuchi's disease (histiocytic necrotizing lymphadenitis) Large plaque parapsoriasis (parapsoriasis en plaques) Lennert lymphoma (lymphoepitheliod lymphoma) Leukemia cutis Lymphoma cutis Lymphomatoid granulomatosis Lymphomatoid papulosis Malignant histiocytosis (histiocytic medullary reticulosis) Marginal zone B-cell lymphoma Mucosa-associated lymphoid tissue lymphoma Mycosis fungoides Non-mycosis fungoides CD30− cutaneous large T-cell lymphoma Nonspecific cutaneous conditions associated with leukemia (leukemid) Pagetoid reticulosis (acral mycoses fungoides, localized epidermotropic reticulosis, mycosis fungoides palmaris et plantaris, unilesional mycosis fungoides, Woringer–Kolopp disease) Pityriasis lichenoides chronica (chronic guttate parapsoriasis, chronic pityriasis lichenoides, dermatitis psoriasiformis nodularis, parapsoriasis chronica, parapsoriasis lichenoides chronica) Pityriasis lichenoides et varioliformis acuta (acute guttate parapsoriasis, acute parapsoriasis, acute pityriasis lichenoides, Mucha–Habermann disease, parapsoriasis acuta, parapsoriasis lichenoides et varioliformis acuta, parapsoriasis varioliformis) Plasmacytoma Plasmacytosis Pleomorphic T-cell lymphoma (non-mycosis fungoides CD30− pleomorphic small/medium-sized cutaneous T-cell lymphoma) Polycythemia vera (erythremia) Primary cutaneous follicular lymphoma (follicular center cell lymphoma, follicular center lymphoma) Primary cutaneous immunocytoma Primary cutaneous marginal zone lymphoma Retiform parapsoriasis Secondary cutaneous CD30+ large cell lymphoma Sézary syndrome Sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease) Subcutaneous T-cell lymphoma (panniculitis-like T-cell lymphoma) Vesiculopustular eruption and leukemoid reaction in Down syndrome
== Further reading == Carson C, Faria G, Hellstrom WJ, Krishnamurti S, Minhas S, Moncada I, et al. (1 January 2010). "Implants, Mechanical Devices, and Vascular Surgery for Erectile Dysfunction". Journal of Sexual Medicine. 7 (1). Wiley: 501–523. doi:10.1111/j.1743-6109.2009.01626.x. PMID 20092450.
Sources: en.wikipedia.org
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.
It usually reports batch-specific results for purity by chromatography, identity by mass spectrometry, and sometimes peptide content and residual solvents. It applies only to the batch tested, not to a supplier's wider stock.
Purity describes the proportion of the chromatographic signal from the target compound, while peptide content measures how much of the vial's physical mass is peptide. Counter-ions, water and residual acid make up the remainder, so content values are commonly lower.
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.